Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Stomach Neoplasms 3Pancreatic Neoplasms 3Carcinoma, Renal Cell 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Lung Neoplasms 2Kidney Neoplasms 2Adenocarcinoma Of Esophagus 2Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Recurrence 1Ovarian Neoplasms 1Metastatic Urothelial Cancer 1Melanoma 1Lung Diseases 1Glioblastoma 1Esophageal Neoplasms 1Erythrocytosis, Familial, 4 1Cholangiocarcinoma 1Advanced Solid Tumors 1Advanced Non-Small Cell Lung Cancer 1

Interventions

zimberelimab 1sacituzumab govitecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urothelial Bladder Carcinoma × zimberelimab × 90 days × Clear all
NCT06133517 2026-03-16

PeRioperative Immunotherapy Combined With Sacituzumab Govitecan in Muscle Invasive blAdder Cancer

Fundación para el Progreso de la Oncología en Cantabria

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡